EQ vs NKTR
EQ: A clinical-stage biotechnology company developing novel aryl hydrocarbon receptor (AhR) modulators for autoimmune and inflammatory diseases. NKTR: A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | EQ | NKTR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.76 | $69.32 | |
| Market cap as of 2026-07-23 | $174M | $2.4B | |
| Net margin as of 2026-07-23 | -19.6% | -280.8% | EQ higher |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | -20.1% | -242.0% | EQ higher |
| ROE as of 2026-07-23 | -61.4% | -45.8% | NKTR higher |
| ROA as of 2026-07-23 | -53.7% | -40.3% | NKTR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.10 | EQ lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -36.2% | |
| Revenue CAGR (3y) SEC XBRL | +61.5% | -15.7% | EQ higher |
| Beta as of 2026-07-23 | 1.85 | 1.13 | |
| 1-year return as of 2026-07-22 close | +541.5% | +183.2% | EQ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.